A promising new treatment could transform outcomes for people facing advanced pancreatic cancer, one of the toughest cancers to beat. In a major clinical trial, the daily pill daraxonrasib nearly doubled average survival time compared with standard chemotherapy, giving patients and families precious extra months together.
Pancreatic cancer often spreads before symptoms appear, which is why more than half of those diagnosed live only three months or less. The disease claims around 10,200 lives in Britain each year. Common warning signs include jaundice, itchy skin, dark urine, pale stools, unexplained weight loss, fatigue and fever, yet these can mimic other conditions and delay diagnosis.
The breakthrough drug works by locking onto and switching off the mutated KRAS gene found in over 90 percent of pancreatic tumours. This targeted approach stops cancer cells from growing while sparing healthy tissue. In the study of 500 patients across North America, Europe and Asia, those taking daraxonrasib lived an average of 13.2 months versus 6.6 months on chemotherapy. Severe side effects were also lower, affecting 43.6 percent of pill users compared with 57.5 percent on chemo.
Experts at the American Society of Clinical Oncology meeting called the results “landscape-changing” for patients with KRAS mutations. Patient advocates say the treatment represents one of the most exciting advances in years and are urging swift access for those who need it most. While more research continues, this pill brings real hope that better, kinder options are finally on the horizon for a disease long starved of progress.
